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Abstract
Background—Sex differences in methamphetamine (METH) use (females>males) have been
demonstrated in clinical and preclinical studies. This experiment investigated the effect of sex on
the reinstatement of METH-seeking behavior in rats and to determine whether pharmacological
interventions for METH-seeking behavior vary by sex. Treatment drugs were modafinil (MOD),
an analeptic, and allopregnanolone (ALLO), a neuroactive steroid and progesterone metabolite.
Method—Male and female rats were trained to self-administer i.v. infusions of METH (0.05mg/
kg/infusion). Next, rats self-administered METH for a 10-day maintenance period. METH was
then replaced with saline, and rats extinguished lever-pressing behavior over 18 days. A multi-
component reinstatement procedure followed where priming injections of METH (1 mg/kg) were
administered at the start of each daily session, preceded 30 min by MOD (128 mg/kg, i.p.), ALLO
(15 mg/kg, s.c.), or vehicle treatment. MOD was also administered at the onset of the session to
determine if it would induce the reinstatement of METH-seeking behavior.
Results—Female rats had greater METH-induced reinstatement responding compared to male
rats following control treatment injections. MOD (compared to the DMSO control) attenuated
METH-seeking behavior in male and female rats; however, ALLO only reduced METH-primed
responding in females. MOD alone did not induce the reinstatement of METH-seeking behavior.
Conclusions—These results support previous findings that females are more susceptible to
stimulant abuse compared to males and ALLO effectively reduced METH-primed reinstatement in
females. Further, they illustrate the utility of MOD as a potential agent for prevention of relapse to
METH use in both males and females.
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While fewer females currently use methamphetamine (METH) than males (SAMHSA
2009), females initiate METH use at earlier ages and display more acute dependence (for
review, see Dluzen and Liu, 2008). Results from animal studies reflect this pattern, showing
that female rats are more sensitive to METH-induced locomotor activity (Milesi-Halle et al.,
2007; Schindler et al., 2002), acquire METH self administration at faster rates, and
administer greater amounts of METH under fixed- and progressive-ratio schedules of
reinforcement (Roth and Carroll, 2004a). While female rats are more prone to stimulant use,
they may also be more receptive to pharmacological treatment interventions. For example,
Cosgrove et al. (2004) found that female rhesus monkeys showed a greater decrease in oral
phencyclidine self administration following bremazocine, and Campbell et al. (2002)
showed that baclofen, a GABAB agonist that has been investigated as a treatment for
stimulant addiction (Roberts, 2005), was more effective at attenuating rates of acquisition of
cocaine self-administration in female rats compared to males. Further, a kappa opioid
agonist was more effective at reducing cocaine-induced locomotor activity in female mice
compare to male mice (Sershen et al., 1998). While these studies suggest greater treatment
receptivity for females, the differential treatment of stimulant abuse with agonist
replacements has not been studied during relapse with males vs. females.
Agonist-based treatment is an emerging strategy for stimulant addiction (Hart et al., 2008;
Herin et al., 2010, but see Castells et al. 2010). Modafinil (MOD) is an agent of this type and
is currently being investigated as treatment for stimulant abuse (Martinez-Raga et al., 2008).
Research with non-human primates has indicated that MOD was effective at reducing
cocaine-maintained responding (Newman et al., 2010). Further, results from a recent clinical
trial indicate that MOD treatment was correlated with increased periods of abstinence in
cocaine addicts with comorbid alcohol dependence (Anderson et al., 2009). This finding was
supported by an experiment that used a preclinical model of relapse (Reichel and See, 2010)
in which MOD was effective at attenuating the reinstatement of METH-seeking behavior in
male rats following conditioned cues and drug-priming injections.
Given the sex-differences in treatment response found in previous studies (Campbell et al.,
2002; Cosgrove and Carroll, 2004; Sershen et al., 1998) and the exclusive use of male rats in
Reichel and See (2010), one aim of the present study was to investigate the possible
differential effects of MOD on the reinstatement of METH-seeking behavior between male
and female rats. Additionally, growing literature is implicating the role of circulating
gonadal hormones in the sex differences observed in substance abuse behaviors (for reviews,
see Anker and Carroll, 2010; Carroll and Anker, 2010; Lynch et al., 2002). Increased risk
for stimulant abuse in females has been associated with higher levels of estrogen (Segarra et
al., 2010), while these effects are attenuated by the progesterone metabolite and positive
GABAA receptor modulator allopregnanolone (ALLO; Anker and Carroll, 2010). Indeed,
ALLO administration attenuated the reinstatement of cocaine-seeking behavior in female,
but not male rats (Anker et al., 2009). Thus, a second aim was to investigate the effects of
ALLO on the reinstatement of METH-seeking behavior in male and female rats. As female
rats respond more during reinstatement following cocaine-priming injections (Anker et al.,
2009), the final aim was to investigate sex differences during METH-primed reinstatement.
In the present experiment male and female rats self-administered i.v. infusions of METH
and then drug-seeking behavior was extinguished. Subsequently, rats were tested on a multi-
component reinstatement procedure in which they received METH priming injections
preceded by ALLO, MOD, or control treatments. Since MOD enhances and ALLO inhibits
dopamine transmission, both treatments were examined within-subjects to compare
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Male (n = 10) and female (n = 9) Wistar rats (Harlan Sprague-Dawley, Inc., Indianapolis,
IN) weighing 350–400 g and 250–300 g, respectively, were used in the present study.
Estrous cycle was allowed to vary randomly in females so that the effects of fluctuating
hormones on drug-seeking behavior would generalize to female rats regardless of cycle
phase. Rats were pair-housed in plastic cages upon arrival in the laboratory, and they had ad
libitum access to food and water. Next, chronic, indwelling catheters were implanted in the
jugular vein as previously described in Carroll and Boe (1982). After they recovered from
surgery, rats were placed in operant conditioning chambers where they remained for the
duration of the study. Throughout the experiment, they were given free access to water and
20 g (males) or 16 g (females) of ground food per day. Rats were housed under a constant
light/dark cycle (12/12-h with room lights on at 6:00 am) in humidity- and temperature- (24°
C) controlled holding rooms. The experimental protocol (1008A87755) was approved by the
University of Minnesota Institutional Animal Care and Use Committee (IACUC), and the
experiment was conducted in accordance with the Principles of Laboratory Animal Care
(National Research Council, 2003) in laboratory facilities accredited by the American
Association for the Accreditation of Laboratory Animal Care.
2.2. Self-administration, extinction, and reinstatement
The drug self-administration apparatus was identical to that described by (Roth and Carroll,
2004b). Briefly, operant chambers were stainless steel and octagon-shaped. They contained
a drinking spout, recessed food receptacle, 2 stimulus lights, one active and one inactive
lever, and a house light. During self-administration sessions the house light was illuminated,
and a response on the active lever resulted in the delivery of an i.v. infusion of METH and
activated the stimulus lights above the lever for the length of the infusion. Responses on the
inactive lever illuminated the stimulus light above the lever but did not result in an infusion.
Initially, rats were trained to lever press for i.v. infusions of METH (0.05 mg/kg/infusion)
during 6-h daily sessions (9:00 am to 3:00 pm). Sessions ended at 3:00 pm or when rats
achieved 40 infusions, whichever came first. Once they self-administered 40 infusions for 3
consecutive days, rats continued responding for METH during 2-h daily sessions (9:00 am
to 11:00 am) for 10 days, but infusions were unlimited. Next, METH was replaced with
saline, and rats extinguished lever responding for a period of 18 days. The house light,
stimulus lights and drug infusion pump were unplugged one day prior to the reinstatement
procedure and remained unplugged for the remainder of the experiment. During
reinstatement, control treatments for ALLO (15 mg/kg, s.c.) and MOD (128 mg/kg, i.p.)
were peanut oil (V, s.c.) and dimethyl sulfoxide (DMSO, i.p.), respectively. These
treatments were administered 30 min before a METH (1 mg/kg, i.p.) priming injection that
was given at the onset of session. Additionally, MOD and DMSO priming injections were
administered alone at the beginning of the session to determine if MOD induced
reinstatement of drug-seeking behavior. The following is an example of the range of the 6
conditions in the reinstatement procedure; however, priming conditions were randomized
across rats to counter possible ordering effects: V+METH, ALLO+METH, DMSO+METH,
MOD+METH, DMSO, MOD. Each of these conditions was preceded by a daily session that
commenced with a saline-priming injection (S).
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d-Methamphetamine HCL (METH) was supplied by the National Institute of Drug Abuse
(Research Triangle Institute, Research Triangle Park, NC) and was dissolved in sterile 0.9%
NaCl saline at a concentration of 0.2 mg METH/mL saline and refrigerated. ALLO was
purchased from Sigma-Aldrich (St. Louis, MO) and was dissolved in peanut oil (20 mg
allopregnanolone/mL peanut oil). MOD was synthesized in the laboratory of Dr. T. E.
Prisinzano (Department of Medicinal Chemistry, The University of Kansas, Lawrence, KS)
and dissolved in DMSO (Sigma-Aldrich) at a concentration of 100 mg MOD/mL DMSO.
2.4. Data analysis
Active and inactive responses and infusions during maintenance and extinction, as well as
active and inactive responses made during reinstatement, served as dependent measures.
Responses and infusions were averaged across two 5-day blocks for the 10-day maintenance
phase, and two 9-day blocks during the 18-day extinction phase. Between-group
comparisons of active and inactive responses and infusions during maintenance and
extinction were analyzed using a 2-factor repeated-measures ANOVA. Between-group
comparisons of responses during reinstatement were analyzed separately with 2-factor
repeated-measures ANOVAs, as shown in the separate panels in Fig. 2. Inactive lever
pressing during reinstatement was similarly analyzed. Post-hoc comparisons were made
between group means using Fischer’s LSD protected t-tests.
3. Results
3.1. Maintenance and Extinction
As shown in Fig. 1, there were no significant differences between males and females in
active lever pressing throughout the maintenance [mean (±SEM) males = 53.3 (±4.4),
females = 52.0 (±3.0)] or extinction [mean (±SEM) males 11.3 (±1.6), females = 15.0
(±1.8)] phases. Responding was stable throughout the maintenance phase for both groups. In
both groups, responding declined over the first 6 extinction sessions and remained at low
and stable levels for the remaining 12 days. There were no significant differences in
responses on the inactive lever during either phase.
3.2. Reinstatement
Fig. 2 shows mean responses on the lever previously associated with METH during the 3
components of the reinstatement procedure. For the MOD component, there were main
effects for treatment (F2,32 = 36.99, p < 0.001) and sex (F1,36 = 12.40, p = .0028), as well as
an interaction between these factors (F2,53 = 8.89. p < 0.001). Female rats showed higher
responding following DMSO+METH compared to males (ps < 0.01), while both males and
females responded more following DMSO+METH compared to MOD+METH and S
conditions (males, ps < 0.05; females ps < 0.01). For the ALLO component, there were main
effects for both treatment (F2,34 = 14.34, p < 0.001) and sex (F1,38=6.02, p=.025), as well as
an interaction between sex and treatment (F2,56 = 5.69, p = 0.007). Female rats responded
more than males following V+METH (ps < 0.05), and only females showed a reduction in
responding when comparing V+METH to ALLO+METH (ps < 0.05). ALLO produced a
39% decrease in responding for females and 0% for males compared to V. Responses made
by the female group following either the V+METH or ALLO+METH conditions (ps < 0.01)
were greater than responses made by females during the S condition. However, males
showed greater responding following ALLO+METH (ps < 0.05) compared to S, but no
difference was found when comparing V+METH to S within this group. There were no
significant differences in reinstatement responding generated by priming injections of MOD
vs. priming injections of DMSO.
Holtz et al. Page 4













For inactive lever responses, there was a significant main effect for treatment (F2,32 = 25.47,
p < 0.001) during the MOD component. Data were combined between males and females,
and post hoc comparisons showed that inactive lever responses were higher following
DMSO+METH compared to both MOD+METH (ps < 0.01) and S (ps < 0.01). There were
no significant results for the ALLO or MOD vs. DMSO components.
4. Discussion
The present study showed that female rats exhibit greater reinstatement of drug-seeking
behavior compared to males following METH-priming injections. This result supports
previous research in which females showed more within- and between-session reinstatement
of cocaine-seeking behavior than males (Anker et al., 2009; Lynch and Carroll, 2000), as
well as clinical data indicating that females may be more prone to relapse to cocaine use
than males (Robbins et al., 1999). Additionally, the results of the present study show that the
attenuating effects of ALLO on female, but not male, cocaine-seeking behavior (Anker et
al., 2009) generalize to METH-seeking behavior as well. MOD again blocked METH-
induced reinstatement responding in male rats as shown by Reichel and See (2010), and the
present study extended these findings to female rats.
Compared to the DMSO vehicle, MOD administration resulted in substantially reduced
METHseeking behavior during reinstatement in both males (97%) and females (87%). In
light of the previous study by Campbell et al. (2002) that indicated a sex-specific treatment
reduction in cocaine acquisition for the GABAB receptor agonist baclofen (females>males),
the current study lends support for agonist-based (vs. inhibitory, e.g., baclofen) treatment
strategies for stimulant addition. The scope of MOD’ neurobiological actions remains
unclear; however, it has been shown to affect different types of neurotransmitters through
multiple mechanisms (Dackis and O'Brien, 2003; Ferraro et al., 1998). For instance, a recent
study suggests that the effectiveness of MOD as a treatment for METH addiction may lie in
its ability to both enhance synaptic dopamine levels and interfere with METH-induced
dopamine increase through modulation of dopamine-transporter functioning (Andersen et
al., 2010; Zolkowska et al., 2009). This dual action of MOD could partially account for its
reduction in the METH-induced reinstatement of drug-seeking behavior in male and female
rats shown in the present experiment. Additionally, since MOD failed to induce
reinstatement, its dopamine-enhancing effects did not result in relapse liability, as has also
been shown in the clinical literature (Anderson et al., 2009; Vosburg et al., 2010).
Regardless of the nature of its specific pharmacological actions, the present study supports
the efficacy of MOD as a possible agent to treat METH addiction.
While there were no sex-differences in the attenuating effects of MOD on METH-induced
reinstatement responding, ALLO predictably reduced METH-primed reinstatement of drug
seeking in females but not males. These results extended the potential treatment effects of
ALLO on METH-induced reinstatement, but only in females. Anker et al (2009) found
similar sex differences with cocaine reinstatement, and this differential action was attributed
to the mediating effects of the circulating gonadal hormones estrogen and progesterone, as
well as the progesterone metabolite ALLO. ALLO is a GABAA positive modulator that is
thought to inhibit the enhancing effect of estrogen on cocaine-seeking behavior (Anker and
Carroll, 2010). This putative effect of estrogen on cocaine-seeking behavior is illustrated by
the greater reinstatement of responding after a METH-priming injection with vehicle
pretreatment in females compared with males. While the present results further implicate
gonadal hormones and their metabolites in the sex-differences found in addiction research,
more work is needed to elucidate the mechanisms driving these differences. In addition to
the present findings, past result suggest that investigating neurobiological differences in
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GABA functions between males and females may be of interest (Campbell et al., 2002; Febo
and Segarra, 2004; Siegal and Dow-Edwards, 2009).
The reduction of inactive lever pressing by MOD following METH priming injections is
likely due to MOS counteracting METH’s potentiation of hyperactivity. However, since all
rats met a 2:1 ratio for active vs. inactive lever pressing ratio following the MOD+METH
condition, active lever responding can be considered to be drug-seeking behavior. Further,
Reichel and See (2010) found no effects of MOD on locomotor activity, and MOD
administered alone had no impact on inactive lever pressing in the present experiment. Thus,
it is improbable that MOD’s attenuation of METH-primed reinstatement responding is due
to a general suppression of activity in the rats. ALLO had no effect on inactive lever
pressing during reinstatement, and that agrees with previous research showing no effect of
ALLO on locomotor activity or food-maintained lever pressing at a dose greater than that
presently tested (Anker et al., 2009).
In summary, female rats showed higher METH-induced reinstatement responding than
males, and MOD was effective in attenuating reinstatement responding in both males and
females. ALLO, however, attenuated reinstatement in female but not male rats. Modafinil’s
therapeutic potential was supported by the inability of MOD to serve as a priming event for
METH-seeking behavior in both male and female rats. The present findings also underscore
the importance of sex-specific treatment strategies for reducing relapse.
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Mean (±SEM) number of responses made for i.v. infusions of methamphetamine (0.05 mg/
kg) on the active lever during maintenance (left) and mean responses made for saline during
the extinction (right). There were no significant differences during these conditions.
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Mean (±SEM) number of responses made on the lever previously drug-paired lever during
all three components of the reinstatement condition. The @ symbol represents significant
within-subject decrease between D+METH and MOD+METH as well as V+METH and A
+METH. The * indicates a within-subject decrease in responding when comparing sessions
with pretreatments and METH priming injections to sessions with S. The # indicates that
females showed greater reinstatement responding compared to males for the D+METH and
V+METH conditions.
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